COVID19 prevention has been a tough nut to crack especially in the Immunocompromised. On one hand, the COVID19 vaccines fell short in patients with moderate to severe weakening of immunity. This included kidney patients with advanced pre-dialysis state, those on dialysis and post-transplant. On the other, in certain kidney patient cohorts who did develop traceable immune response to the vaccines ended up with a flaring of pre-existing underlying autoimmune kidney diseases like IgA Nephropathy.
Then we have Evusheld ® – drug maker AstraZeneca’s new long acting monoclonal antibody combo shot. This antibody drug (generic name: AZD7442) was granted an Emergency Use Authorization by the USFDA on December 8th, 2021. With its “ready-made immune protection”, this long acting antibody (LAAB) drug shows promise in preventing symptomatic COVID19 in immunocompromised patients (just like vaccines do in immunocompetent). However, only time will tell how well it performs on-field. Read more here.
But then, amidst this steady inflow of pharmacological strategies to ward-off COVID19, if something has managed to survive it’s the utility of the humble face mask. Of-course, other COVID safe practices like following strict hygiene protocols and avoiding crowds go hand-in-hand.